Search

Displaying results 7261 - 7270 of 9714 in total
  1. Drug

    Ozagrel

    go.drugbank.com/drugs/DB12017
    Investigational

    Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes.

    Categories: Thromboxane-A Synthase, antagonists & inhibitors
  2. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  3. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory … accelerated approval on August 13, 2026, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a

  4. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases … [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key

  5. Drug

    Doravirine

    go.drugbank.com/drugs/DB12301
    ApprovedInvestigational

    [L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).

  6. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth. … [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  7. Drug

    Navitoclax

    go.drugbank.com/drugs/DB12340
    Investigational

    It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.

  8. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  9. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.

  10. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent.